These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31475573)

  • 1. Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats.
    Melo-Carrillo A; Strassman AM; Schain AJ; Noseda R; Ashina S; Adams A; Brin MF; Burstein R
    Cephalalgia; 2019 Oct; 39(11):1358-1365. PubMed ID: 31475573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors' responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle?
    Zhang X; Strassman AM; Novack V; Brin MF; Burstein R
    Cephalalgia; 2016 Aug; 36(9):875-86. PubMed ID: 26984967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the effects of extracranial injections of botulinum toxin type A on activation and sensitization of central trigeminovascular neurons by cortical spreading depression in male and female rats.
    Melo-Carrillo A; Strassman AM; Malcolm KJ; Adams AM; Dabruzzo B; Briode RS; Brin MF; Burstein R
    Cephalalgia; 2024 Sep; 44(9):3331024241278919. PubMed ID: 39252510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors.
    Melo-Carrillo A; Strassman AM; Nir RR; Schain AJ; Noseda R; Stratton J; Burstein R
    J Neurosci; 2017 Nov; 37(44):10587-10596. PubMed ID: 28972120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains.
    Burstein R; Zhang X; Levy D; Aoki KR; Brin MF
    Cephalalgia; 2014 Oct; 34(11):853-69. PubMed ID: 24694964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons.
    Melo-Carrillo A; Strassman AM; Schain AJ; Adams AM; Brin MF; Burstein R
    Cephalalgia; 2021 Jan; 41(1):17-32. PubMed ID: 33200944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OnabotulinumtoxinA affects cortical recovery period but not occurrence or propagation of cortical spreading depression in rats with compromised blood-brain barrier.
    Melo-Carrillo A; Strassman AM; Schain AJ; Broide RS; Cai BB; Rhéaume C; Brideau-Andersen AD; Ashina S; Flores-Montanez Y; Brin MF; Burstein R
    Pain; 2021 Sep; 162(9):2418-2427. PubMed ID: 34448754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atogepant - an orally-administered CGRP antagonist - attenuates activation of meningeal nociceptors by CSD.
    Strassman AM; Melo-Carrillo A; Houle TT; Adams A; Brin MF; Burstein R
    Cephalalgia; 2022 Aug; 42(9):933-943. PubMed ID: 35332801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of intracranial meningeal nociceptor activity by cortical spreading depression: a reassessment.
    Zhao J; Levy D
    J Neurophysiol; 2015 Apr; 113(7):2778-85. PubMed ID: 25695654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissociation between CSD-Evoked Metabolic Perturbations and Meningeal Afferent Activation and Sensitization: Implications for Mechanisms of Migraine Headache Onset.
    Zhao J; Levy D
    J Neurosci; 2018 May; 38(22):5053-5066. PubMed ID: 29703787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel insight into atogepant mechanisms of action in migraine prevention.
    Melo-Carrillo A; Strassman AM; Broide R; Adams A; Dabruzzo B; Brin M; Burstein R
    Brain; 2024 Aug; 147(8):2884-2896. PubMed ID: 38411458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective Inhibition of Trigeminovascular Neurons by Fremanezumab: A Humanized Monoclonal Anti-CGRP Antibody.
    Melo-Carrillo A; Noseda R; Nir RR; Schain AJ; Stratton J; Strassman AM; Burstein R
    J Neurosci; 2017 Jul; 37(30):7149-7163. PubMed ID: 28642283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ezogabine (KCNQ2/3 channel opener) prevents delayed activation of meningeal nociceptors if given before but not after the occurrence of cortical spreading depression.
    Zhang X; Jakubowski M; Buettner C; Kainz V; Gold M; Burstein R
    Epilepsy Behav; 2013 Aug; 28(2):243-8. PubMed ID: 23562239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura.
    Zhang X; Levy D; Noseda R; Kainz V; Jakubowski M; Burstein R
    J Neurosci; 2010 Jun; 30(26):8807-14. PubMed ID: 20592202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine.
    Levy D; Burstein R; Strassman AM
    Ann Neurol; 2005 Nov; 58(5):698-705. PubMed ID: 16240341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous mechanisms underlying the activation and sensitization of meningeal nociceptors: the role of immuno-vascular interactions and cortical spreading depression.
    Levy D
    Curr Pain Headache Rep; 2012 Jun; 16(3):270-7. PubMed ID: 22328144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?
    Pellesi L; Do TP; Ashina H; Ashina M; Burstein R
    Headache; 2020 Jun; 60(6):1056-1065. PubMed ID: 32437038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of Peripheral and Central Trigeminovascular Neurons by Seizure: Implications for Ictal and Postictal Headache.
    Melo-Carrillo A; Schain AJ; Strassman AM; Burstein R
    J Neurosci; 2020 Jul; 40(27):5314-5326. PubMed ID: 32527981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for antinociceptive activity of botulinum toxin type A in pain management.
    Aoki KR
    Headache; 2003; 43 Suppl 1():S9-15. PubMed ID: 12887389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meningeal P2X7 Signaling Mediates Migraine-Related Intracranial Mechanical Hypersensitivity.
    Zhao J; Harrison S; Levy D
    J Neurosci; 2023 Aug; 43(33):5975-5985. PubMed ID: 37487740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.